Historical Stock Chart
6 Months : From Sep 2019 to Mar 2020
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Thursday that it has received marketing authorization from China's national medical products administration for Imfinzi for the treatment of patients with stage III nonsmall-cell lung cancer.
The U.K. pharmaceuticals company said approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III Pacific trial.
Write to Adriano Marchese at firstname.lastname@example.org
(END) Dow Jones Newswires
December 12, 2019 02:38 ET (07:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.